Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP100:ES209-217(210M) Peptide Immunization in Metastatic Melanoma
NCT00001705Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 1998
- Modality
- Modified Peptides, Vaccines & Immunotherapeutics, Native Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of gp100:209-217(210M) in melanoma (3 arms), sponsored by National Cancer Institute. Primary endpoint: Clinical Response. Started Jul 1998; status: completed.
02
Drugs
gp100:209-217(210M)
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00001705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001705.